$BTAX
Biostax Corp. Stock $btax

$btax Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040859 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$268.0K	$233.1K	$420.9K
YoY Change	5.24%	-44.61%	267.34%
% of Gross Profit
Research & Development	$65.87K	$105.8K
YoY Change	362.57%
% of Gross Profit
Depreciation & Amortization	$13.78K	$13.78K
YoY Change
% of Gross Profit
Operating Expenses	$293.3K	$352.3K	$420.9K
YoY Change	9.09%	-16.29%
Operating Profit		-$352.3K	-$420.9K
YoY Change		-16.29%	267.35%
Interest Expense	-$48.11K	$36.44K	$11.03K
YoY Change	261.73%	230.22%	-134.27%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$36.44K	-$2.073M
YoY Change		-98.24%	-178.02%
Pretax Income	-$341.5K	-$388.8K	-$2.493M
YoY Change	22.41%	-84.41%	-180.1%
Income Tax
% Of Pretax Income
Net Earnings	-$341.5K	-$388.8K	-$2.493M
YoY Change	22.41%	-84.41%	-180.1%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00	-$0.04
Diluted Earnings Per Share	$0.00	$0.00	-$0.04
COMMON SHARES
Basic Shares Outstanding	83.66M shares	83.62M shares	71.08M shares
Diluted Shares Outstanding		83.24M shares	60.09M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.79K	$4.530K	$191.0K
YoY Change	-80.2%	-97.63%	-92.89%
Cash & Equivalents	$29.79K	$4.531K	$185.4K
Short-Term Investments			$5.500K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$29.79K	$4.531K	$190.9K
YoY Change	-80.21%	-97.63%	-92.89%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.500K	$5.500K
YoY Change	-89.16%
Total Long-Term Assets	$713.7K	$727.5K	$0.00
YoY Change	-12.24%
TOTAL ASSETS
Total Short-Term Assets	$29.79K	$4.531K	$190.9K
Total Long-Term Assets	$713.7K	$727.5K	$0.00
Total Assets	$743.5K	$732.0K	$190.9K
YoY Change	-22.85%	283.35%	-92.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.351M	$1.350M	$1.385M
YoY Change	3.89%	-2.54%	-36.56%
Accrued Expenses	$136.1K	$136.1K	$176.1K
YoY Change	0.0%	-22.72%	-95.74%
Deferred Revenue
YoY Change
Short-Term Debt	$2.289M	$1.984M	$761.5K
YoY Change	109.73%	160.52%	-80.33%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.559M	$4.212M	$2.793M
YoY Change	31.12%	50.79%	-73.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.559M	$4.212M	$2.793M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.559M	$4.212M	$2.793M
YoY Change	31.12%	50.79%	-73.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$384.6M	-$384.3M	-$382.7M
YoY Change	0.43%	0.41%
Common Stock	$380.8M	$380.8M	$380.1M
YoY Change	0.09%	0.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.816M	-$3.480M	-$2.602M
YoY Change
Total Liabilities & Shareholders Equity	$743.5K	$732.0K	$190.9K
YoY Change	-22.85%	283.35%	-92.89%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$341.5K	-$388.8K	-$2.493M
YoY Change	22.41%	-84.41%	-180.1%
Depreciation, Depletion And Amortization	$13.78K	$13.78K
YoY Change
Cash From Operating Activities	-$88.07K	$11.06K	-$436.1K
YoY Change	-121.22%	-102.54%	364.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00		$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	113.3K	-23.95K	350.0K
YoY Change	126.66%	-106.84%	250.01%
NET CHANGE
Cash From Operating Activities	-88.07K	11.06K	-436.1K
Cash From Investing Activities	0.000		0.000
Cash From Financing Activities	113.3K	-23.95K	350.0K
Net Change In Cash	25.26K	-12.89K	-86.09K
YoY Change	-172.27%	-85.03%	-1502.12%
FREE CASH FLOW
Cash From Operating Activities	-$88.07K	$11.06K	-$436.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities		usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001559356
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
CY2022Q3	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
CY2023Q3	BTAX	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations		usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q3	BTAX	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock		usd
CY2022Q3	BTAX	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock		usd
	BTAX	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock		usd
	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement		usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization		usd
	BTAX	Common Stock Issued For Extension Of Patent And License Agreement CommonStockIssuedForExtensionOfPatentAndLicenseAgreement		usd
	BTAX	Increase Decrease In License Fees Payable IncreaseDecreaseInLicenseFeesPayable		usd
	BTAX	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodExercisePrice
	BTAX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAveragePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-54933
	dei	Entity Registrant Name EntityRegistrantName	BIOSTAX CORP
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-3226705
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2431 Aloma Ave.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 124
	dei	Entity Address City Or Town EntityAddressCityOrTown	Winter Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32792
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	613-8802
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83657853	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4531	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150491	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	4531	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	150491	usd
CY2023Q3	BTAX	Patents And Licenses PatentsAndLicenses	721969	usd
CY2022Q4	BTAX	Patents And Licenses PatentsAndLicenses	762500	usd
CY2023Q3	us-gaap	Deposits Assets DepositsAssets	5500	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	50728	usd
CY2023Q3	us-gaap	Assets Assets	732000	usd
CY2022Q4	us-gaap	Assets Assets	963719	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1349816	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1300366	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	336002	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1118978	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	121544	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	64455	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	136057	usd
CY2023Q3	BTAX	License Fees Payable Current LicenseFeesPayableCurrent	284630	usd
CY2022Q4	BTAX	License Fees Payable Current LicenseFeesPayableCurrent	549079	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4211861	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3477173	usd
CY2023Q3	us-gaap	Liabilities Liabilities	4211861	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3477173	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83620764	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83620764	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	83045857	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	83045857	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8362	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8305	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380779078	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380436432	usd
CY2023Q3	BTAX	Stock To Be Issued StockToBeIssued	10303	usd
CY2022Q4	BTAX	Stock To Be Issued StockToBeIssued	10303	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384277604	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382968494	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3479861	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	732000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	963719	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	233109	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	420862	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	689111	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	894596	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105837	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	461969	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13377	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	40531	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	352323	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	420862	usd
	us-gaap	Operating Expenses OperatingExpenses	1191611	usd
	us-gaap	Operating Expenses OperatingExpenses	894596	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-352323	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-420862	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1191611	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-894596	usd
	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
CY2022Q3	BTAX	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations	-1467271	usd
	BTAX	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations	-40000	usd
	BTAX	Gain Loss On Assignment Of Obligations GainLossOnAssignmentOfObligations	-1169691	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	594288	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
	BTAX	Impairment Loss On Investment In Common Stock ImpairmentLossOnInvestmentInCommonStock	2645000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	36437	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	11034	usd
	us-gaap	Interest Expense InterestExpense	77499	usd
	us-gaap	Interest Expense InterestExpense	107102	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36437	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2072593	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117499	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2362555	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-388760	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2493455	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1309110	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-388760	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2493455	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1309110	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3257151	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83239115	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60089305	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83461806	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20643181	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83239115	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60089305	shares
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	150491	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83461806	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20643181	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-7948256	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6202919	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95973	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	698324	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1605913	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2602278	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2513454	usd
	BTAX	Stock Issued During Period Value Issued For Extension Of Patent And License Agreement StockIssuedDuringPeriodValueIssuedForExtensionOfPatentAndLicenseAgreement	300000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	42703	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1309110	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3479861	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3479861	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1309110	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3257151	usd
	BTAX	Gain Loss On Issuance Of License Agreement GainLossOnIssuanceOfLicenseAgreement	3165151	usd
	BTAX	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-40000	usd
	BTAX	Gain Loss On Settlement Of Obligations GainLossOnSettlementOfObligations	-1169691	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2645000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1605913	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	40531	usd
	BTAX	Common Stock Issued For Extension Of Patent And License Agreement CommonStockIssuedForExtensionOfPatentAndLicenseAgreement	300000	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-45228	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	5500	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	39450	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-75895	usd
	BTAX	Increase Decrease In License Fees Payable IncreaseDecreaseInLicenseFeesPayable	-264449	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	4620	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	69792	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	116929	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-35321	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	470098	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-568460	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-996865	usd
	BTAX	Proceeds From Undocumented Investor Advances ProceedsFromUndocumentedInvestorAdvances	6369	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	417058	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	322500	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	265000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	422500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	688427	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-145960	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-308438	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	493885	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4531	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	185447	usd
	BTAX	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	42703	usd
	BTAX	Conversion Of Notes And Accrued Interest To Common Stock ConversionOfNotesAndAccruedInterestToCommonStock	6901242	usd
	us-gaap	Stock Issued1 StockIssued1	95973	usd
CY2023Q3	us-gaap	Cash Cash	4531	usd
CY2023Q3	BTAX	Working Capital WorkingCapital	4207330	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-384277604	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1309110	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3257151	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zj812peGJ1pj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zDQBVol0Wxp5">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4531	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150491	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_z2d6s4xhFlJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zlEz8N7Sj8Yc">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20230930_z7tk728RXxxi" title="Cash at federal deposit">250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	461969	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	50000	shares
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	93500	usd
CY2022Q3	us-gaap	Share Price SharePrice	1.87
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-388760	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2493455	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83239115	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60089305	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-388760	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2493455	usd
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83239115	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60089305	shares
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1309110	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3257151	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83461806	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20643181	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1309110	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3257151	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	83461806	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20643181	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1118978	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	696478	usd
CY2023Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	121544	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	64455	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31995	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	38495	shares
CY2022Q4	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	59.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	6500	shares
	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAveragePrice	73.85
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	31995	shares
CY2023Q3	BTAX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAveragePrice	56.49
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure

Files In Submission

Name	View Source	Status
0001493152-23-040859-index-headers.html	Edgar Link	pending
0001493152-23-040859-index.html	Edgar Link	pending
0001493152-23-040859.txt	Edgar Link	pending
0001493152-23-040859-xbrl.zip	Edgar Link	pending
btax-20230930.xsd	Edgar Link	pending
btax-20230930_def.xml	Edgar Link	unprocessable
btax-20230930_cal.xml	Edgar Link	unprocessable
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
btax-20230930_lab.xml	Edgar Link	unprocessable
btax-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BTAX
Biostax Corp. Stock $btax

2023 Q4 Form 10-Q Financial Statement

#000149315223040859 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX Biostax Corp. Stock $btax

2023 Q4 Form 10-Q Financial Statement

#000149315223040859 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BTAX
Biostax Corp. Stock $btax